Rezdiffra — Blue Cross Blue Shield of Kansas
metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (stage F2–F3) without cirrhosis
Initial criteria
- Patient is age ≥ 18 years
- Diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) or nonalcoholic steatohepatitis (NASH) confirmed by liver biopsy or noninvasive methods showing fibrosis stage F2 or F3
- No evidence of cirrhosis (fibrosis stage F4 or higher)
- Prescriber attests that the patient will continue lifestyle modification (diet, exercise, alcohol avoidance, weight loss) alongside pharmacologic therapy
Reauthorization criteria
- Patient has demonstrated stability or improvement in liver fibrosis or biochemical markers of steatohepatitis upon review
- Prescriber attests therapy remains clinically appropriate and well-tolerated
Approval duration
12 months